MindMed’s MM120 Shows Promise in Treating Generalized Anxiety Disorder

An update from Mind Medicine ( (MNMD) ) is now available.

Mind Medicine announced that the Journal of the American Medical Association (JAMA) has published results from the first-ever randomized, placebo-controlled clinical trial assessing the efficacy of MM120, a form of LSD, in treating Generalized Anxiety Disorder (GAD). The Phase 2b study showed that a 100 µg dose of MM120 achieved significant improvements in anxiety symptoms compared to placebo, with a 65% clinical response rate and 48% clinical remission rate at Week 12. The study’s positive results have led to the FDA granting Breakthrough Therapy Designation to MM120, highlighting its potential as a new treatment option for GAD, a condition affecting millions of adults in the U.S. with limited effective treatments.

The most recent analyst rating on (MNMD) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Mind Medicine stock, see the MNMD Stock Forecast page.

Spark’s Take on MNMD Stock

According to Spark, TipRanks’ AI Analyst, MNMD is a Neutral.

Mind Medicine’s stock score is primarily impacted by its weak financial performance, marked by zero revenue and substantial net losses typical of clinical-stage biotech firms. The strong liquidity position is offset by reliance on equity financing. Technical analysis shows moderate positive momentum, but valuation metrics are unattractive with a negative P/E ratio. The lack of earnings call data and corporate events leaves financial performance as the dominant factor in the overall score.

To see Spark’s full report on MNMD stock, click here.

More about Mind Medicine

Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company focused on developing novel product candidates to treat brain health disorders.

Average Trading Volume: 1,231,783

Technical Sentiment Signal: Strong Buy

Current Market Cap: $701.5M

See more data about MNMD stock on TipRanks’ Stock Analysis page.